業(yè)執(zhí)照.jpg)
黃楊堿
分析標(biāo)準(zhǔn)品,T≥99%
Cyclovirobuxine
CAS號(hào)：860-79-7
分子式：C26H46N2O
分子量：402.66
MDL：MFCD00468040
貨號(hào) | 規(guī)格/參數(shù)/品牌 | 價(jià)格 | 貨期 |
YJ-B20573-20mg | 分析標(biāo)準(zhǔn)品,T≥99% | ￥300.00 | 現(xiàn)貨 |
JS31427-1g | ≥98% | ￥924.00 | 現(xiàn)貨 |
JS31427-5g | ≥98% | ￥2324.00 | 現(xiàn)貨 |
JS31427-25g | ≥98% | ￥5550.00 | 2-3天 |
JS31427-100g | ≥98% | ￥13000.00 | 2-3天 |
產(chǎn)品介紹
熔點(diǎn)：218-220℃
沸點(diǎn)：495.7 ℃ at 760 mmHg
外觀：無(wú)色針狀結(jié)晶
溶解性：在氯仿中易溶，在甲醇或乙醇中溶解，在丙tong中略溶，在水中微溶。
儲(chǔ)存條件：2-8℃
注意：部分產(chǎn)品我司僅能提供部分信息，我司不保證所提供信息的權(quán)威性，僅供客戶(hù)參考交流研究之用。
參考文獻(xiàn)(7篇)
7. [IF=10.7] Yingying Shao et al."Targeting LIF With Cyclovirobuxine D to Suppress Tumor Progression via LIF/p38MAPK/p62-Modulated Mitophagy in Hepatocellular Carcinoma."MedComm.2025 May;6(6):e70227
6. [IF=4.9] Yun-Hao Ren et al."Unlocking the Stratum Corneum Barrier to Skin Penetration for the Transdermal Delivery of Cyclovirobuxine D."Pharmaceutics.2024 Dec;16(12):1600
5. [IF=3.1] Gao Ke et al."Suppressing the progression of bladder cancer using cyclovirobuxine D based on network pharmacology and bioinformatics approaches."NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY.2025 Jan;:1-19
4. [IF=6.8] Yiman Liu et al."Repurposing cyclovirobuxine D as a novel inhibitor of colorectal cancer progression via modulating the CCT3/YAP axis."BRITISH JOURNAL OF PHARMACOLOGY.2024 Jul;:
3. [IF=5] Ke Gao et al."DNA repair pathways-targeted cyclovirobuxine inhibits castration-resistant prostate cancer growth by promoting cell apoptosis and cycle arrest."Translational Oncology.2023 Sep;35:101708
2. [IF=3.417] Lingqi Zhou et al."Cyclovirobuxine D inhibits cell proliferation and migration and induces apoptosis in human glioblastoma multiforme and low?grade glioma."Oncol Rep. 2020 Mar;43(3):807-816
1. 增夏,關(guān)懷敏,王賀,邱承杰,趙亞楠,曹英杰,解金紅.環(huán)維黃楊星D對(duì)H_2O_2損傷大鼠心房肌細(xì)胞L型鈣通道的影響[J].廣東醫(yī)學(xué),2020,41(16):1631-1636.
